Sign In
Buy GLP
$49.26
+1.26 (+2.63%)
At Close: Jun 02, 2026
Global Partners: Valuation Is Favorable (Rating Upgrade)
12:03am, Monday, 11'th May 2026
Global Partners LP is upgraded from hold to buy as valuation and technicals turn favorable after a period of market-driven weakness. GLP's Q1 2026 revenue surged 16% YoY to $5.3B, with operating margi
Global Partners Q1 Earnings Call Highlights
11:12am, Sunday, 10'th May 2026
Global Partners NYSE: GLP reported a sharply higher first-quarter profit and cash flow, with management citing colder weather in the Northeast, stronger wholesale and commercial conditions, and improv
Global Partners LP Common Units (GLP) Q1 2026 Earnings Call Transcript
04:21pm, Friday, 08'th May 2026
Global Partners LP Common Units (GLP) Q1 2026 Earnings Call Transcript
Wells Fargo Downgrades Nike to Equal Weight: GLP-1 Mega-Trend Threatens the Athletic Wear Giant
11:21am, Friday, 08'th May 2026
Wells Fargo just delivered a contrarian gut check to Nike (NYSE:NKE | NKE Price Prediction) stock bulls, downgrading the athletic wear giant to Equal Weight from Overweight and trimming its price targ
New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market
10:30am, Friday, 08'th May 2026
� Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms.
Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market
10:05am, Friday, 08'th May 2026
Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish pharmaceutical giant. And both UBS and Citi are high
Global Partners LP Reports First-Quarter 2026 Financial Results
08:00am, Friday, 08'th May 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) today reported financial results for the first quarter ended March 31, 2026. CEO Commentary “Solid execution across all operating segm
Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support
04:10pm, Thursday, 07'th May 2026
SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada w
Retatrutide Black Market: Why Consumers Will Do Anything To Get Eli Lilly's New GLP
12:10pm, Thursday, 07'th May 2026
Eli Lilly's next-generation weight-loss drug, Retatrutide, could hit the shelves soon. Though the treatment has yet to attain FDA approval, demand is already so heavy that consumers are going to the b
Functional Brands Inc. Announces Launch of GLP-Squared Injection
08:00am, Wednesday, 06'th May 2026
Proprietary Semaglutide + Tirzepatide Dual-Peptide Formulation Now Available Exclusively Through the Tru2u.health Platform Lake Oswego, Portland--(Newsfile Corp. - May 6, 2026) - Functional Brands Inc
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
02:11pm, Tuesday, 05'th May 2026
Lilly's Foundayo is off to a strong start, drawing new prescribers and patients as broad pharmacy access and payer coverage fuel early oral obesity momentum.
Promino Responds to Growing Demand for Muscle Health Support as Health Canada Expands Access to Semaglutide
07:00am, Tuesday, 05'th May 2026
Rejuvenate Muscle Health™ Adds Prominent GLP-1 Support Call-Out to New Packaging Set to Debut Later This Month Across North America; ECRM "Best Drink 2025" Validation; Promino™ NSF Certified for S
Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%
04:50pm, Monday, 04'th May 2026
The hosts of Morning Brew Daily made a simple argument on a recent episode that the idea of the “Ozempic economy” should be replaced with the “Mounjaro economy” now that Eli Lilly is controlli
Novo Nordisk's Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance
02:04pm, Monday, 04'th May 2026
Novo Nordisk's Wegovy pill has created another boom in the GLP-1 drug market. Eli Lilly recently introduced its Foundayo pill for weight loss, three months after the launch of its rival's drug.
New York City, NY, May 04, 2026 (GLOBE NEWSWIRE) -- DISCLAIMER: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription medications t
